Press release

Sensyne Health enters into a research collaboration to apply AI for clinical trial design

December 23, 2019

Oxford, UK: Sensyne Health plc (LSE: SENS), the British clinical AI technology company, today announced it has signed a research project with Roche. Initially the collaboration will focus on identifying patient populations in one disease area and assessing and collating anonymised patient data with anonymised electronic patient record (EHR) information to support clinical trial planning. No financial terms were disclosed.  

The planned collaboration will be Sensyne Health’s second successive partnership with a major pharmaceutical company following the announcement in July 2019 of a collaboration agreement with Bayer to accelerate the clinical development of new treatments for cardiovascular disease.

Lord (Paul) Drayson PhD, CEO of Sensyne Health plc, said:
“This is an important collaboration and marks Sensyne’s increasing activity in partnering with leading pharmaceutical companies using our clinical AI platform. It is particularly pleasing given Roche’s progressive approach to data and technology-driven personalised healthcare.”

-ENDS-

For more information please contact:

Sensyne Health
+44 (0) 330 058 1845

Lord (Paul) Drayson, Chief Executive Officer
Lorimer Headley, Chief Financial Officer

Peel Hunt LLP (Nominated Adviser and Joint Broker)
+ 44 (0) 20 7418 8900

Dr Christopher Golden
James Steel
Oliver Jackson

Liberum (Joint Broker)
+ 44 (0) 20 3100 2000

Bidhi Bhoma
Euan Brown

Consilium Strategic Communications
+44 20 3709 5700

Mary-Jane Elliott
Sukaina Virji
Melissa Gardiner
sensynehealth@consilium-comms.com

About Sensyne Health

Sensyne Health plc is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company’s access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts. This is to ensure that the purpose of the anonymisation and the proposed analysis are subject to appropriate ethical oversight and information governance, including conformance with NHS principles, UK data protection law and applicable regulatory guidance. Sensyne Health is an early signatory to the Department of Health and Social Care’s ‘Initial Code of Conduct for data-driven health and care technology.

Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).

Press release

Sensyne Health enters into a research collaboration to apply AI for clinical trial design

December 23, 2019

Oxford, UK: Sensyne Health plc (LSE: SENS), the British clinical AI technology company, today announced it has signed a research project with Roche. Initially the collaboration will focus on identifying patient populations in one disease area and assessing and collating anonymised patient data with anonymised electronic patient record (EHR) information to support clinical trial planning. No financial terms were disclosed.  

The planned collaboration will be Sensyne Health’s second successive partnership with a major pharmaceutical company following the announcement in July 2019 of a collaboration agreement with Bayer to accelerate the clinical development of new treatments for cardiovascular disease.

Lord (Paul) Drayson PhD, CEO of Sensyne Health plc, said:
“This is an important collaboration and marks Sensyne’s increasing activity in partnering with leading pharmaceutical companies using our clinical AI platform. It is particularly pleasing given Roche’s progressive approach to data and technology-driven personalised healthcare.”

-ENDS-

For more information please contact:

Sensyne Health
+44 (0) 330 058 1845

Lord (Paul) Drayson, Chief Executive Officer
Lorimer Headley, Chief Financial Officer

Peel Hunt LLP (Nominated Adviser and Joint Broker)
+ 44 (0) 20 7418 8900

Dr Christopher Golden
James Steel
Oliver Jackson

Liberum (Joint Broker)
+ 44 (0) 20 3100 2000

Bidhi Bhoma
Euan Brown

Consilium Strategic Communications
+44 20 3709 5700

Mary-Jane Elliott
Sukaina Virji
Melissa Gardiner
sensynehealth@consilium-comms.com

About Sensyne Health

Sensyne Health plc is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company’s access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts. This is to ensure that the purpose of the anonymisation and the proposed analysis are subject to appropriate ethical oversight and information governance, including conformance with NHS principles, UK data protection law and applicable regulatory guidance. Sensyne Health is an early signatory to the Department of Health and Social Care’s ‘Initial Code of Conduct for data-driven health and care technology.

Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).

Press release

Sensyne Health enters into a research collaboration to apply AI for clinical trial design

Sensyne Health enters into a research collaboration to apply AI for clinical trial design

December 23, 2019

Oxford, UK: Sensyne Health plc (LSE: SENS), the British clinical AI technology company, today announced it has signed a research project with Roche. Initially the collaboration will focus on identifying patient populations in one disease area and assessing and collating anonymised patient data with anonymised electronic patient record (EHR) information to support clinical trial planning. No financial terms were disclosed.  

The planned collaboration will be Sensyne Health’s second successive partnership with a major pharmaceutical company following the announcement in July 2019 of a collaboration agreement with Bayer to accelerate the clinical development of new treatments for cardiovascular disease.

Lord (Paul) Drayson PhD, CEO of Sensyne Health plc, said:
“This is an important collaboration and marks Sensyne’s increasing activity in partnering with leading pharmaceutical companies using our clinical AI platform. It is particularly pleasing given Roche’s progressive approach to data and technology-driven personalised healthcare.”

-ENDS-

For more information please contact:

Sensyne Health
+44 (0) 330 058 1845

Lord (Paul) Drayson, Chief Executive Officer
Lorimer Headley, Chief Financial Officer

Peel Hunt LLP (Nominated Adviser and Joint Broker)
+ 44 (0) 20 7418 8900

Dr Christopher Golden
James Steel
Oliver Jackson

Liberum (Joint Broker)
+ 44 (0) 20 3100 2000

Bidhi Bhoma
Euan Brown

Consilium Strategic Communications
+44 20 3709 5700

Mary-Jane Elliott
Sukaina Virji
Melissa Gardiner
sensynehealth@consilium-comms.com

About Sensyne Health

Sensyne Health plc is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company’s access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts. This is to ensure that the purpose of the anonymisation and the proposed analysis are subject to appropriate ethical oversight and information governance, including conformance with NHS principles, UK data protection law and applicable regulatory guidance. Sensyne Health is an early signatory to the Department of Health and Social Care’s ‘Initial Code of Conduct for data-driven health and care technology.

Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).

Press release

Sensyne Health enters into a research collaboration to apply AI for clinical trial design

Sensyne Health enters into a research collaboration to apply AI for clinical trial design

Oxford, UK: Sensyne Health plc (LSE: SENS), the British clinical AI technology company, today announced it has signed a research project with Roche. Initially the collaboration will focus on identifying patient populations in one disease area and assessing and collating anonymised patient data with anonymised electronic patient record (EHR) information to support clinical trial planning. No financial terms were disclosed.  

The planned collaboration will be Sensyne Health’s second successive partnership with a major pharmaceutical company following the announcement in July 2019 of a collaboration agreement with Bayer to accelerate the clinical development of new treatments for cardiovascular disease.

Lord (Paul) Drayson PhD, CEO of Sensyne Health plc, said:
“This is an important collaboration and marks Sensyne’s increasing activity in partnering with leading pharmaceutical companies using our clinical AI platform. It is particularly pleasing given Roche’s progressive approach to data and technology-driven personalised healthcare.”

-ENDS-

For more information please contact:

Sensyne Health
+44 (0) 330 058 1845

Lord (Paul) Drayson, Chief Executive Officer
Lorimer Headley, Chief Financial Officer

Peel Hunt LLP (Nominated Adviser and Joint Broker)
+ 44 (0) 20 7418 8900

Dr Christopher Golden
James Steel
Oliver Jackson

Liberum (Joint Broker)
+ 44 (0) 20 3100 2000

Bidhi Bhoma
Euan Brown

Consilium Strategic Communications
+44 20 3709 5700

Mary-Jane Elliott
Sukaina Virji
Melissa Gardiner
sensynehealth@consilium-comms.com

About Sensyne Health

Sensyne Health plc is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company’s access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts. This is to ensure that the purpose of the anonymisation and the proposed analysis are subject to appropriate ethical oversight and information governance, including conformance with NHS principles, UK data protection law and applicable regulatory guidance. Sensyne Health is an early signatory to the Department of Health and Social Care’s ‘Initial Code of Conduct for data-driven health and care technology.

Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).

Arrange to meet us
Press release

Sensyne Health enters into a research collaboration to apply AI for clinical trial design

December 23, 2019

Oxford, UK: Sensyne Health plc (LSE: SENS), the British clinical AI technology company, today announced it has signed a research project with Roche. Initially the collaboration will focus on identifying patient populations in one disease area and assessing and collating anonymised patient data with anonymised electronic patient record (EHR) information to support clinical trial planning. No financial terms were disclosed.  

The planned collaboration will be Sensyne Health’s second successive partnership with a major pharmaceutical company following the announcement in July 2019 of a collaboration agreement with Bayer to accelerate the clinical development of new treatments for cardiovascular disease.

Lord (Paul) Drayson PhD, CEO of Sensyne Health plc, said:
“This is an important collaboration and marks Sensyne’s increasing activity in partnering with leading pharmaceutical companies using our clinical AI platform. It is particularly pleasing given Roche’s progressive approach to data and technology-driven personalised healthcare.”

-ENDS-

For more information please contact:

Sensyne Health
+44 (0) 330 058 1845

Lord (Paul) Drayson, Chief Executive Officer
Lorimer Headley, Chief Financial Officer

Peel Hunt LLP (Nominated Adviser and Joint Broker)
+ 44 (0) 20 7418 8900

Dr Christopher Golden
James Steel
Oliver Jackson

Liberum (Joint Broker)
+ 44 (0) 20 3100 2000

Bidhi Bhoma
Euan Brown

Consilium Strategic Communications
+44 20 3709 5700

Mary-Jane Elliott
Sukaina Virji
Melissa Gardiner
sensynehealth@consilium-comms.com

About Sensyne Health

Sensyne Health plc is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company’s access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts. This is to ensure that the purpose of the anonymisation and the proposed analysis are subject to appropriate ethical oversight and information governance, including conformance with NHS principles, UK data protection law and applicable regulatory guidance. Sensyne Health is an early signatory to the Department of Health and Social Care’s ‘Initial Code of Conduct for data-driven health and care technology.

Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).